A Consortium Model
For Biomarker Research

Shawnmarie Mayrand-Chung, Ph.D./J.D.
NIH Director for The Biomarkers Consortium
October 2009
Goals of The Biomarkers Consortium

- Facilitate the discovery, development, and validation of biomarkers using new and existing technologies
- Help qualify biomarkers for specific applications in:
  - diagnosing disease
  - predicting therapeutic response
  - improving clinical practice
- Generate data useful to inform regulatory decision-making
- Make consortium project results broadly available to the entire scientific community -- “biomarker resources”
Governance Structure

Executive Committee
NIH / FDA / INDUSTRY
CMS / Public-Patient Representative / Foundation for NIH

Steering Committees
Project Teams

Cancer
Inflammation & Immunity
Metabolic Disorders
Neuroscience

Project 1
Project 1
Project 1
Project 1
Project 1
Project 2
Project 2
Project 1
(No SC)
The Biomarkers Consortium Executive Committee

**Chairman**
Charles Sanders, Foundation for NIH

**NIH**
Thomas Insel, NIMH
John Niederhuber, NCI
Lawrence Tabak, NIDCR

**FDA**
ShaAvhree Buckman,
   *Office of Translational Science*
Dan Schultz,
   *Center for Devices & Radiological Health*
Janet Woodcock,
   *Director of CDER*

**Public Member**
Mary Woolley, Research!America

**Centers for Medicare & Medicaid Services**
Barry Straube

**Industry**
Stephen Eck, Eli Lilly & Co.
Gary Herman, Merck & Co., Inc.
Garry Neil, Johnson & Johnson
Sara Radcliffe, BIO

**Foundation for NIH Board**
Steve Paul, Eli Lilly & Co.
Ellen Sigal, Friends of Cancer Research
Cancer
– Anna Barker, National Cancer Institute
– David Parkinson, Nodality, Inc.

Inflammation and Immunity
– Daniel Rotrosen, NIAID
– Bruce Littman, Translational Medicine Assocs. (ex-Pfizer)

Metabolic Disorders
– David Kelley, Merck and Co., Inc.
– Myrlene Staten, National Institute of Diabetes and Digestive and Kidney Diseases

Neuroscience
– Huda Akil, University of Michigan
– William Potter, Merck and Co., Inc.
Principles and Policies

Key governing policies have been pre-negotiated with the stakeholders (and their legal counsel) representing FNIH, NIH, FDA, PhRMA, CMS and BIO:

- Antitrust
- Confidentiality
- Conflict of Interest
- Intellectual Property
- Data sharing
- Grant Awards / Contractor Selection

Note: Policies, concept submission forms, and other information available at: www.biomarkersconsortium.org
Project Development Process

1. Initial Idea or Concept
   - Scientific merit
   - Pre-competitive
   - Feasibility
   - Initial funding scan

2. Approved Project Concept
   - Steering Committee

3. Project Plan
   - Protocol
   - Resources
   - Intellectual property
   - Data sharing and distribution
   - Timelines and milestones
   - Budget
   - Human subjects
   - Privacy
   - Legal review

4. Approved Project
   - Executive Committee (VOTE)
   - Final QA/QC
   - Funding

5. Launch
   - Project Team (execution)
   - Steering Committee (oversight)
   - Contracts
   - Project Management

RFA/RFP “HIBOs” or External Submission
Strategic focus on high impact areas of biomarker development and validation:

- **Important:** addresses a significant unmet/scientific need
- **Translational:** will result in significant improvement in the development, approval or delivery of care to patients
- **Transformational:** addresses critical gaps
- **Feasible:** end goals can be likely achieved in a specific timeframe
- **Practical:** leverages pre-existing resources wherever possible
- **Fundable:** is capable of generating the required funding/stakeholder support needed
- **Unique:** not already substantially being done elsewhere
- **Collaborative:** would uniquely benefit from the multi-stakeholder composition and approach of The Biomarkers Consortium
# Contributing Members (49)

## For-Profit Companies (19)

<table>
<thead>
<tr>
<th>Company Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott Laboratories</td>
</tr>
<tr>
<td>Althea Technologies</td>
</tr>
<tr>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Avalon Pharmaceuticals</td>
</tr>
<tr>
<td>BG Medicine, Inc.</td>
</tr>
<tr>
<td>Boehringer-Ingelheim Pharmaceuticals</td>
</tr>
<tr>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td>Digilab Biovision GmbH</td>
</tr>
<tr>
<td>EMD Serono, Inc.</td>
</tr>
<tr>
<td>Genstruc, Inc.</td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>GVK Biosciences</td>
</tr>
<tr>
<td>InfraReDx, Inc.</td>
</tr>
<tr>
<td>Ingenuity Systems</td>
</tr>
<tr>
<td>Johnson &amp; Johnson</td>
</tr>
<tr>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Luminex Corporation</td>
</tr>
<tr>
<td>H. Lundbeck A/S</td>
</tr>
<tr>
<td>Merck and Co., Inc.</td>
</tr>
<tr>
<td>Metabolon, Inc.</td>
</tr>
<tr>
<td>Novartis Pharmaceutical Corp.</td>
</tr>
<tr>
<td>Novo Nordisk</td>
</tr>
<tr>
<td>Pfizer, Inc.</td>
</tr>
<tr>
<td>F. Hoffmann-La Roche</td>
</tr>
<tr>
<td>Rules-Based Medicine, Inc.</td>
</tr>
<tr>
<td>Scout Diagnostics</td>
</tr>
<tr>
<td>Wyeth</td>
</tr>
</tbody>
</table>

## Non-Profit Companies (30)

<table>
<thead>
<tr>
<th>Company Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Academy of Molecular Imaging</td>
</tr>
<tr>
<td>Advanced Medical Technology Association</td>
</tr>
<tr>
<td>Alliance for Aging Research</td>
</tr>
<tr>
<td>Alzheimer’s Association</td>
</tr>
<tr>
<td>American Association for Cancer Research</td>
</tr>
<tr>
<td>American College of Neuropsychopharmacology</td>
</tr>
<tr>
<td>American Health Assistance Foundation</td>
</tr>
<tr>
<td>American Society of Clinical Oncology</td>
</tr>
<tr>
<td>American Society for Clinical Pharmacology and Therapeutics</td>
</tr>
<tr>
<td>American Society for Therapeutic Radiology and Oncology</td>
</tr>
<tr>
<td>Association of Clinical Research Organizations</td>
</tr>
<tr>
<td>Autism Speaks</td>
</tr>
<tr>
<td>Avon Foundation</td>
</tr>
<tr>
<td>Battelle Memorial Institute</td>
</tr>
<tr>
<td>Biotechnology Industry Organization</td>
</tr>
<tr>
<td>CHDI Foundation</td>
</tr>
<tr>
<td>Cystic Fibrosis Foundation</td>
</tr>
<tr>
<td>Federation of Clinical Immunology Societies</td>
</tr>
<tr>
<td>The Hamner Institutes for Health Sciences</td>
</tr>
<tr>
<td>The Immune Tolerance Institute, Inc.</td>
</tr>
<tr>
<td>Juvenile Diabetes Research Foundation</td>
</tr>
<tr>
<td>Kidney Cancer Association</td>
</tr>
<tr>
<td>The Leukemia and Lymphoma Society</td>
</tr>
<tr>
<td>Michael J. Fox Foundation for Parkinson’s Research</td>
</tr>
<tr>
<td>Ontario Cancer Biomarker Network</td>
</tr>
<tr>
<td>Pharmaceutical Research and Manufacturers of America</td>
</tr>
<tr>
<td>Radiological Society of North America</td>
</tr>
<tr>
<td>Ryan Licht Sang Bipolar Foundation</td>
</tr>
<tr>
<td>Society for Nuclear Medicine</td>
</tr>
<tr>
<td>University of Illinois</td>
</tr>
<tr>
<td>Project Name/Committee</td>
</tr>
<tr>
<td>-------------------------------------------------------------</td>
</tr>
<tr>
<td>FDG-PET Lung and Lymphoma Projects (CSC)</td>
</tr>
<tr>
<td>Circulating Tumor Cells in Metastatic Prostate Cancer (CSC)</td>
</tr>
<tr>
<td>DCE-MRI Technique Optimization Using Prostate Cancer as a Model System (CSC)</td>
</tr>
<tr>
<td>Detection and Characterization of Circulating Tumor Cells in Prospective Treatment Trial of Neoadjuvant and Metastatic Breast Cancer (CSC)</td>
</tr>
</tbody>
</table>

Note: 2 projects
## Approved Projects to Date (continued)

<table>
<thead>
<tr>
<th>Project Name/Committee</th>
<th>Execution Objective</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>PET Imaging of Inflammation in Rheumatoid Arthritis (Immunity &amp; Inflammation SC)</td>
<td>Perform a feasibility study to determine the potential clinical utility of PET imaging as a biomarker to indicate active inflammation in RA</td>
<td>Approved for execution Q3 2009 (8/2009)</td>
</tr>
<tr>
<td>Adiponectin Project (Metabolic Disorders SC)</td>
<td>Determine whether adiponectin has utility as a predictive biomarker of glycemic control</td>
<td>Completed – publications released in July 2009</td>
</tr>
<tr>
<td>Carotid MRI Reproducibility Project (Metabolic Disorders SC)</td>
<td>Establish a standardized carotid MRI protocol and impact of site/platform on reproducibility</td>
<td>Launched Q3 2008; 18 month project</td>
</tr>
<tr>
<td>Sarcopenia Consensus Summit (Metabolic Disorders SC)</td>
<td>Generate a consensus definition of sarcopenia (age-related decrease in skeletal muscle mass) to provide specific guidelines for diagnosis/better enable regulatory decisions</td>
<td>First phase launched July 2009; two year project</td>
</tr>
<tr>
<td>Alzheimer’s Disease Targeted Plasma Proteomics Project (Neuroscience SC)</td>
<td>Qualify a multiplexed panel of known AD plasma-based biomarkers using plasma samples from the Alzheimer’s Disease Neuroimaging Initiative</td>
<td>Launched 12/2008; one year project</td>
</tr>
<tr>
<td>Project Name/Committee</td>
<td>Execution Objective</td>
<td>Status</td>
</tr>
<tr>
<td>------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>PET Radioligand Project (Neuroscience SC)</td>
<td>Develop improved, more sensitive radioligands with higher binding to the peripheral benzodiazepine receptor</td>
<td>Launched 3/2009; two year project</td>
</tr>
<tr>
<td>Placebo Data Analysis in Alzheimer's Disease and Mild Cognitive Impairment Clinical Trials (Neuroscience SC)</td>
<td>Combine placebo data from large industry clinical trials and analyze them to provide better measures of cognition and disease progression for use in future AD/MCI clinical trials</td>
<td>Approved for execution Q2 2009 (6/2009)</td>
</tr>
<tr>
<td>Alzheimer's Disease Targeted CSF Proteomics Project (Neuroscience SC)</td>
<td>Qualify a multiplexed panel of known AD CSF-based biomarkers; examine Beta-Site APP Cleaving Enzyme levels in CSF; and qualify a mass spectroscopy panel as a tool to diagnose and monitor disease progression using CSF samples from the Alzheimer's Disease Neuroimaging Initiative</td>
<td>Approved for execution Q2 2009 (6/2009)</td>
</tr>
<tr>
<td>Metabolomics Signatures and Biomarkers for Depression and its Treatment (Neuroscience SC)</td>
<td>Conduct a comprehensive metabolomic analysis of soluble and lipid metabolites, including neurotransmitter-related metabolites, coupled with statistical analysis and data mining in order to identify metabolic signatures (biomarkers) that predict early and/or late response to SSRIs</td>
<td>Approved for execution Q3 2009 (8/2009)</td>
</tr>
</tbody>
</table>
### Pipeline: Next Project

<table>
<thead>
<tr>
<th>Project Name</th>
<th>Execution Objective</th>
<th>Expected Cost/Duration</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>I-SPY-2 Adaptive Breast Cancer Trial [<em>Cancer</em>]</td>
<td>Breakthrough biomarker-based adaptive trial design in neoadjuvant setting in high-risk breast cancer patients</td>
<td>~$8-9 million / 5 years</td>
<td>September 2009 EC</td>
</tr>
</tbody>
</table>
## Longer Term Pipeline: Project Teams/Working Groups

<table>
<thead>
<tr>
<th>Activity</th>
<th>Execution Objective</th>
<th>Estimated Cost/Duration</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Markers of Immune Status Working Group [Immunity &amp; Inflammation]</strong></td>
<td>Develop robust testing platforms that can be used to monitor markers of immune function in clinical trials</td>
<td>$3-4M / 2 years</td>
<td>Working group formed; developing project plan</td>
</tr>
<tr>
<td><strong>Atherosclerosis Working Group [Metabolic Disorders]</strong></td>
<td>Use modeling approach to identify a panel of Phase II biomarkers that predict Phase III outcomes in 6 months or less; second phase will identify subjects at higher risk than current risk engines via focused prospective trial</td>
<td>TBD</td>
<td>The working group’s strategy document will be presented to the EC in June 2009</td>
</tr>
<tr>
<td><strong>Beta Cell Function Working Group [Metabolic Disorders]</strong></td>
<td>Develop a consensus statement on best current and potential approaches to assess beta cell function and factors that influence beta cell function → specific project(s) to be defined</td>
<td>TBD</td>
<td>Symposium held on April 15-16, 2009; consensus statement under development that will be presented to the EC in August 2009</td>
</tr>
</tbody>
</table>
Shawnmarie Mayrand-Chung, Ph.D./J.D.
NIH Program Director, The Biomarkers Consortium

Public-Private Partnership Program
Office of Science Policy, OSPA
Office of the Director
National Institutes of Health
Building 1 - Room 213, MSC 0166
Phone: 301-435-1705
Fax: 301-402-0280
Email: mayrands@od.nih.gov

Senior Advisor, The Biomarkers Consortium
Foundation for the NIH
9650 Rockville Pike, Room 3301
Bethesda, MD 20814
Phone: (301) 402-4333
www.biomarkersconsortium.org
# Current Active Projects: Relative Industry to NIH Contributions

<table>
<thead>
<tr>
<th>Project Name/Committee/Duration</th>
<th>Private Sector Support (in $1,000s)</th>
<th>NIH Support (Grants &amp; in-kind, in $1,000s)*</th>
<th>Grand Total</th>
<th>Cost Share: Industry %</th>
<th>Cost Share: NIH %</th>
</tr>
</thead>
<tbody>
<tr>
<td>FDG-PET Lung and Lymphoma Projects (CSC – 60 months) [2 projects]</td>
<td>6,570 (9 funders)</td>
<td>3,750</td>
<td>10,320</td>
<td>64%</td>
<td>36%</td>
</tr>
<tr>
<td>Adiponectin Project (MDSC – 9 months)</td>
<td>0 (data sharing project)</td>
<td>0</td>
<td>0</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Carotid MRI Reproducibility Project (MDSC – 18 months)</td>
<td>957 (3 funders)</td>
<td>1,020</td>
<td>1,977</td>
<td>48%</td>
<td>52%</td>
</tr>
<tr>
<td>ADNI Targeted Plasma Proteomics (NSC – 9 months)</td>
<td>450 (funded through ADNI surplus)</td>
<td>500</td>
<td>950</td>
<td>47%</td>
<td>53%</td>
</tr>
<tr>
<td>PET Radioligand Project (NSC – 24 months)</td>
<td>561 (6 funders)</td>
<td>500</td>
<td>1,061</td>
<td>53%</td>
<td>47%</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>$8,538</strong></td>
<td><strong>$5,770</strong></td>
<td><strong>$14,308</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Estimated

---

**Grand Total**

- Industry: 64%
- NIH: 36%
- Total: 100%
Private Sector Participation in The Biomarkers Consortium

- Allows for the *leveraging of financial and scientific resources* from industry, government (FDA, NIH, CMS) and foundations and other non-profit organizations

- Industry participation offers new opportunities to:
  - maximize investment in clinical research programs
    - pool samples & data from completed trials
  - combine industry, government and academic expertise
  - “piggyback” onto existing research studies and clinical trials
  - *spread financial and scientific risk*
  - explore scientific basis for new regulatory pathways
Contributing Membership Program

- Provides operational funds to the Foundation for NIH to operate the Consortium
- Allows all sectors to participate in the activities of the Consortium

Membership Benefits
- Elect three (3) representatives to serve on the Executive Committee
- Nominate individuals to serve on Steering Committees (created to date in cancer, immunity & inflammation, metabolic disorders, and neuroscience) and Project Teams (developing individual projects)
- Participate in “high-impact biomarkers” prioritization process
- Propose project concepts and ideas for potential Consortium execution

Annual Membership Dues
- Companies: $5,000-$100,000 per year (depending on annual sales)
- Non-profits: $5,000 per year
Adiponectin Project: Study Design

- **Phase 1**
  - Baseline evaluation to confirm the validity of the dataset

- **Phase 2**
  - Evaluate change of adiponectin vs. change of the other variables

- **Phase 3**
  - Examine prognostic value change in adiponectin at "early" times to predict HbA1c response
I-SPY TRIAL 2 uses an adaptive trial design to identify successful treatment regimens for Stage II/III breast cancer based on specific biomarkers.

**Step 1: Stratify the patients into two arms based on HER2 receptor status**

- **Stratifying Biomarkers:**
  - Class I/II devices: HER2 (IHC, FISH), MammaPrint, ER, PR
  - IDE: MammaPrint44K, Her2 (RPMA, 44K-microarray)

  **New agents will be tested in both arms**

  **An adaptive design will improve these assignments as the trial proceeds, benefiting patients.**
The Utility of Adiponectin as a Biomarker for Predicting Glycemic Efficacy
Approved: October 2007 -- Status: Completed in January 2009

• Can the protein adiponectin serve as a predictive biomarker for glycemic control in Type II diabetes patients being treated with peroxisome proliferator-activated receptor agonists (PPARs)?

• Four pharmaceutical companies (Merck, Eli Lilly, Roche, GlaxoSmithKline) provided pre-existing data from clinical trials to third-party independent statisticians (Quintiles and NIDDK) who pooled, standardized, and analyzed blinded data to determine whether a relationship between adiponectin and glucose or HbA1C levels could be established.

• This data sharing project found that adiponectin was a robust predictor of glycemic response to PPAR agonists in Type II Diabetic Patients, but also in healthy individuals.*

*The results were presented at the American Society for Clinical Pharmacology and Therapeutics meeting in March 2009, at the American Diabetes Association meeting in June 2009, and are published in the July 2009 issue of Clinical Pharmacology and Therapeutics.
Adiponectin Results Highlights

• **Project Goal**: Determine whether adiponectin has utility as a predictive biomarker of glycemic control in normal non-diabetic subjects and patients with Type II diabetes

• Adiponectin is a robust predictor of glycemic response to PPAR agonists, but not non-PPAR drugs, in T2D patients

• Previous findings about the relationship between adiponectin levels and metabolic parameters (HbA1C, HDL, hematocrit) were confirmed by this analysis

• The potential utility of adiponectin across the spectrum of glucose tolerance was demonstrated

• **This project established an approach to cross-company collaboration that embodies a robust, feasible approach to future biomarker qualification**
Active Projects
FDG-PET Lung and Lymphoma Projects

**FDG-PET Imaging in Non Hodgkin’s Lymphoma to Predict Tumor Response to Treatment**

**Phase II Study of FDG-PET/CT as a Predictive Marker of Tumor Response and Patient Outcome: Prospective Validation in Non-Small Cell Lung Cancer**

**Project Goals:**
- Determine the linkage of FDG-PET to the effect of therapy and drugs on clinical outcome and survival in lymphoma and lung cancer
- Develop standard protocols for acquiring and evaluating FDG-PET data
- Evaluate robustness and clinical feasibility of protocols

**Value:**
- More efficient drug development
- Inform the regulatory review process and approval path
- Better early response criteria
- Ability to cost-share the qualification of FDG-PET
Active Project
Carotid MRI Reproducibility Study via an NHLBI AIM-HIGH Ancillary Study

**Project Participants:** University of Washington, NHLBI, Abbott, Merck, Pfizer, FDA

**Project Goals:**
- Establish a standardized carotid MRI protocol at 15 centers with 3T whole body MRI scanners (using GE and Philips scanners)
- Provide training and standardized imaging sequences and carotid phased-array coils to all sites
- Add reproducibility scan at all sites (n=80)
- Determine the impact of site and platform on reproducibility

**Project Duration and Budget:**
- 18-month, $957K study from 3 private funders ($1.02M provided by NHLBI)

**Dissemination of Results:** Results to be submitted for publication first and then posted on The Biomarkers Consortium website
**Active Project**

**Use of Targeted Multiplex Proteomic Strategies to Identify Plasma-Based Biomarkers in Alzheimer’s Disease**

**Need:**
- Simple biochemical tools to identify early AD and monitor treatment effects on disease progression

**Opportunity:**
- Utilize plasma biofluids from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) approved for use in assessing the utility of existing AD biomarker panels as tools for disease progression and identification of early AD

**Objectives:**
- Qualify known plasma-based biomarkers
  - Indicate change in disease progression
  - Serve as useful endpoints to be modified by drug treatment
  - Support disease modification drug trials

**Strategies:**
- Qualify plasma-based (151 analytes) multiplex panel composed of a subset of biomarkers identified in prior proteomic studies (next phase of project (CSF) to be pursued in 2009)
- Characterize the aβpeptide species present in plasma

**Project Duration/Budget:**
- 6 months / $0.4M
- Results available by April 2009 – funds available in-house at FNIH to conduct this project
**Active Project**

**Comparison of Two PET Radioligands Labeled with $^{11}$C or $^{18}$F to Quantify the Peripheral Benzodiazepine Receptor**

**Need:** New radioligands with higher specific binding to PBR -- Limits to $[^{11}\text{C}](\text{R})$-PK 11195 (prototypical tracer):
- low brain uptake, causing poor signal-to-noise
- amounts of specific binding too low for stable quantitative analysis
- study results difficult to interpret

**Opportunity:** Two new radioligands, $[^{11}\text{C}]$PBR28 and $[^{18}\text{F}]$FBR, have shown significantly higher specific binding to PBR than $[^{11}\text{C}](\text{R})$-PK 11195 in preliminary studies

**Objective:** Develop improved, more sensitive and more quantifiable radioligands

**Project Goals:**
- Assess the utility of these two radioligands to image and quantify inflammation in the periphery and the brain in Alzheimer’s Disease and Atherosclerosis
- Determine the time course/role of inflammation in different brain disorders/periphery and utility as biomarkers to assess the efficacy of agents designed to increase/decrease inflammatory markers

**Project Duration and Budget:**
- Two years, $1M (to be equally funded by NIMH/private sector – 6 companies) – launched in Q1 2009

**Dissemination of Results:** All results will be published via peer-reviewed journal and/or Consortium website